Pulmonary delivery of plasmid DNA (pDNA)/cationic liposome complexes is associated with an acute unmethylated CG dinucleotide (CpG)-mediated inflammatory response and brief duration of transgene expression. We demonstrate that retention of even a single CpG in pDNA is sufficient to elicit an inflammatory response, whereas CpG-free pDNA vectors do not. Using a CpG-free pDNA expression vector, we achieved sustained (Z56 d) in vivo transgene expression in the absence of lung inflammation.
Nonviral gene therapy vectors are being evaluated for the treatment of a range of inherited and acquired diseases. Such synthetic vectors have an advantage over commonly used viral vectors for the treatment of chronic, inherited diseases, such as cystic fibrosis (CF), because of their ability to be administered repeatedly without the generation of a limiting immune response 1 . However, clinical studies of the lungs of CF subjects show that current nonviral formulations direct modest, transient transgene expression that is associated with a mild but appreciable host inflammatory reaction 2 . In an attempt to increase both the safety and efficacy of nonviral gene transfer for CF, we have systematically modified the pDNA component of our preferred nonviral formulation. We assessed the impact of alternative transcriptional elements and pDNA CpG content on the duration of transgene expression and the severity of inflammatory symptoms associated with lung delivery.
Our first-generation (pG1) expression pDNA vectors (Supplementary Fig. 1 online) used the common cytomegalovirus (CMV) enhancer/promoter element to drive transgene expression with the ColE1 bacterial origin of replication and could be efficiently delivered to the airways by noninvasive aerosolization after complexing with the cationic lipid formulation GL67A 3 . However, transgene expression directed by pG1-CMV after in vivo aerosol delivery lasted only B2 weeks in both clinical 2 and preclinical studies (Fig. 1a) . We replaced the viral enhancer/promoter elements with the human ubiquitin C (UbC) promoter (details in Supplementary Methods online) to determine whether loss of transgene expression was due to transcriptional silencing rather than loss of pDNA or transfected cells 4, 5 . Use of the UbC promoter resulted in a modest but encouraging increase in the duration of transgene expression ( Fig. 1a; pG1-UbC).
Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) cDNA expression mediated by first-generation pDNA vectors 
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was sufficient to transiently correct the underlying CF chloride channel defect in the nose and lung of treated CF subjects 2 . However, pG1/GL67A delivery was also associated with a mild 'flu-like' inflammatory syndrome in clinical studies 2, 6 and increased levels of inflammatory cells and cytokines within the lungs after delivery to mice ( Fig. 2a-d ). This lung inflammation may be related to the interaction of the host's Toll-like receptor 9-dependent innate immune system 7 and CpGs in the pDNA 8, 9 . We hypothesized that CpG reduction might both reduce the inflammatory response and increase the magnitude and duration of transgene expression and, in turn, therapeutic efficacy. Therefore, we designed second-generation (pG2) pDNA vectors incorporating a range of eukaryotic transcriptional elements in which the CpG content was reduced from B300 CpGs for a typical first-generation pDNA vector to B200 CpGs ( Supplementary Fig. 1 ).
Six pG2 vectors (149-262 CpGs) containing alternative enhancer/ promoter combinations ( Supplementary Fig. 1 ) were evaluated in the mouse aerosol model. pG2-CMV, pG2-EF1a (human elongation factor 1 alpha promoter), pG2-CEF1a (human CMV enhancer coupled to EF1a), pG2-CUBI (human CMV enhancer coupled to the human ubiquitin B promoter) and pG2-CUCI (human CMV enhancer coupled to the UbC promoter) did not direct peak lung transgene expression levels higher than those obtained with pG1-CMV (Fig. 1b) . However, pG2-UbC, containing the UbC promoter, directed sustained expression at levels that were initially low, but increased over time such that at 14 and 28 d after delivery they exceeded those observed with pG1-UbC (P o 0.04) and were similar to the peak level attained by pG1-CMV at 1 d after delivery (P 4 0.32) (Fig. 1b) . Disappointingly, pG2 pDNA vectors, including pG2-UbC, elicited lung inflammation that was as robust as noted with pG1 pDNA vectors ( Fig. 2a-d) .
Subsequently, we hypothesized that only pDNA vectors that were entirely free of CpGs would fail to elicit a profound inflammatory response, and, therefore, we constructed third-generation (pG3) pDNA vectors that were entirely CpG-free or contained only a single CpG (Supplementary Fig. 1 ). Previous attempts to construct CpGfree pDNA vectors were hindered by the loss of ColE1 origin of replication activity after CpG depletion 10 . Instead, we used a CpG-free form of the R6K origin of replication ( Supplementary Fig. 1 ) that supported pDNA replication in E. coli hosts containing the R6K pir gene product 11 . Testing these vectors after topical delivery to the mouse lung showed that pDNA vectors containing only a single CpG elicited inflammation at levels that were significantly higher than those obtained with CpG-free pDNA (Fig. 2a-d) . Crucially, levels of host inflammation directed by CpG-free pDNA were statistically indistinguishable from vehicle alone after topical lung (Fig. 2a-d ) or systemic intravenous ( Supplementary Fig. 2 online) delivery.
Subsequently fourth-generation (pG4) CpG-free pDNA vectors containing alternative CpG-free enhancer/promoter combinations (pG4-CMV, pG4-EFI, pG4-mCEFI and pG4-hCEFI; Supplementary  Fig. 1 ) were evaluated in the mouse aerosol model. Unlike the pG3 pDNA vectors described above, pG4 pDNA vectors are compliant with published guidance regarding the use of pDNA as an investigative pharmaceutical 12, 13 . Lung transgene expression at early time-points after pG4-CMV delivery was similar to that observed with pG1-CMV and pG2-CMV pDNA vector (Fig. 1a-c) . Lung transgene expression with pG4-EFI harboring a CpG-free human elongation factor 1 alpha promoter was very low at all time-points assessed, but the addition of a CpG-free version of either the murine or human CMV enhancer (pG4-mCEFI and pG4-hCEFI, respectively) had a dramatic impact on the expression profile (Fig. 1c) . Whereas transgene expression directed by pG4-mCEFI was transient (like pG4-CMV), the peak expression levels observed were higher than those of any other first-or secondgeneration pDNA vectors and were only surpassed by those of pG4-hCEFI. The latter directed modest lung transgene expression at early time-points but significantly higher lung transgene expression than all other pDNA vectors tested by days 14 and 28 after administration (P o 0.001).
Consequently, we constructed a pG4-hCEFI derivative in which the transgene was a CFTR cDNA with all CpG motifs eliminated and codon usage optimized to enhance translation ( Supplementary  Fig. 3 online) . pG4-hCEFI-soCFTR2 (sometimes also termed pGM169) directed robust in vitro expression of the B170-kDa glycosylated CFTR protein (Fig. 3a) and generated cAMP-activated chloride channel activity with a pharmacological profile indistinguishable from that of native human CFTR (Fig. 3b,c) . Furthermore, pG4-hCEFI-soCFTR2, like other CpG-free pDNA vectors (Fig. 2) , did not elicit lung inflammation when complexed with GL67A (data not shown) and directed sustained in vivo expression of CFTR mRNA for at least 56 d after aerosol delivery to the mouse lung (Fig. 3d) at levels exceeding the 5% of endogenous levels widely assumed to be therapeutic 14, 15 .
In summary, our data demonstrate that (i) optimization of pDNA structure is crucial for maximizing in vivo gene transfer; (ii) pDNA containing only a single CpG can be sufficient to elicit a robust inflammatory response; (iii) sustained transgene expression in the absence of inflammation can be achieved with CpG-free nonviral vectors and (iv) the transgene expression levels may be sufficient to provide a therapeutic response in CF. These results suggest that use of CpG-free pDNA expression vectors could advance the nonviral gene transfer field by minimizing host inflammatory responses in the clinic.
Note: Supplementary information is available on the Nature Biotechnology website.
